Release Date: December 21, 2023
Expiration Date: December 21, 2024
Activity Overview
This online activity is designed to update clinicians on data presented at the 23rd EURETINA Congress, held October 5-8 in Amsterdam, the Netherlands, and will help facilitate critical assessment and clinical integration of these and other data in appropriate patients. The activity focuses on recently approved treatments for nAMD and DME that have evidence supporting longer treatment intervals. Expert thought leaders provide insights into how clinicians can apply these findings to their clinical practice to improve patient care.
Target Audience
This educational activity is directed towards retina specialists and other ophthalmologists.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize emerging evidence regarding the management of retinal diseases as presented at major medical conferences in 2023
- Identify appropriate patient populations who may benefit from evidence-based therapies used in the management of nAMD based on clinical presentation and goals of treatment
. - Identify appropriate patient populations who may benefit from evidence-based therapies used in the management of DME based on clinical presentation and goals of treatment
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
